Assertion Supported AI assessment confidence: 95% certainty 4/5 debate potential 2/5

Afeyan: Celera sequenced the genome because the government project was too slow

Noubar Afeyan · Moderna and Flagship Pioneering: Noubar Afeyan · Oct 11, 2021 · at 26:19

Noubar Afeyan explains why Perkin-Elmer and Celera Genomics launched an independent, commercial race against the publicly funded Human Genome Project.

0:00 / 0:15exact quote · 16.0s

720p mp4 · rendered on demand · StarZero watermark

“We needed to sequence the genome first, and we at first thought maybe the government can, the government's effort at the time would suffice, but it was going fairly slowly, and so we launched a, what It became a competitive effort, although it wasn't fully intended to be competitive in the first instance.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

Celera Genomics launched its private genome sequencing initiative because the public Human Genome Project was progressing too slowly.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

Historical records and contemporaneous documentation from the May 1998 founding of Celera Genomics confirm that the initiative was explicitly launched due to the perception that the publicly funded Human Genome Project was progressing too slowly. In 1998, the public project was projected to finish by 2005; Celera (named after the Latin word for speed) was established to complete the sequence in three years by 2001. Contemporaneous statements and congressional testimony by co-founder J. Craig Venter directly cited the slow pace, bureaucratic structure, and high costs of the government effort as primary justifications for launching Celera under mottos such as 'Speed matters' and 'Discovery can't wait.'

In May 1998, Perkin-Elmer and J. Craig Venter founded Celera Genomics (derived from the Latin 'celeritas', meaning speed) to complete the human genome by 2001, in contrast to the public Human Genome Project's 2005 target.
Contemporaneous statements and April 2000 congressional testimony by Craig Venter explicitly documented that Celera launched to accelerate sequencing because the federal effort was progressing too slowly on a 15-year timeline.

Checked against

[1] jcvi.org [2] newspaperarchive.com [3] encyclopedia.com [4] wikipedia.org [5] yourgenome.org [6] archives.gov [7] nih.gov [8] cshl.edu

Perkin Elmer Craig Venter May 1998 announcement Human Genome Project speed "Celera" "celerity" meaning speed "Craig Venter" New York Times May 1998 Craig Venter Perkin Elmer genome sequencing company "May 10, 1998" "Venter" "human genome" "Perkin-Elmer" Celera Genomics 1998 Perkin Elmer Craig Venter public Human Genome Project slow

assessed as of 2026-09-03

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

Celera Human Genome Project

⚑ Spot an error? Report it

More from Noubar Afeyan

Insight

Afeyan: The romantic 'hero founder' startup folklore is largely unnecessary

“There's a lot of folklore in the startup world, which I'd say emphasizes the role of the individual. There's a hero kind of notion that's created, you know, against all odds. And here we were claiming that conceiving, creating, growing companies could be the o…”

Noubar Afeyan Oct 11, 2021 ▶ 34:35 Moderna and Flagship Pioneering: Noubar Afeyan

Insight

Afeyan: Precision in guessing what works is unimportant when pioneering new fields

“The accuracy with which you have to guess what's going to work Is not at all important. Because we get into these brand new areas, it's wide open to find where value lies, right? Imagine if we waited three, four years as people did, or 10 years in the case of …”

Noubar Afeyan Oct 11, 2021 ▶ 44:00 Moderna and Flagship Pioneering: Noubar Afeyan

Insight

Afeyan: Long biotech lifecycles prevent serial entrepreneurship, forcing internal talent creation

“In biotech, these companies have a half-life or a life cycle of, say, 10 years, 15 years. So people don't do one company after another. If they do one company after 1015 years and they succeed, they stop doing it. So you have to create the talent.”

Noubar Afeyan Oct 11, 2021 ▶ 33:04 Moderna and Flagship Pioneering: Noubar Afeyan

Assertion Not checkable as stated

Afeyan: Nobody took mRNA research seriously as recently as 2016

“Five years ago, nobody was taking MRNA research seriously”

Noubar Afeyan Oct 11, 2021 ▶ 36:23 Moderna and Flagship Pioneering: Noubar Afeyan

Assertion Supported

Afeyan: 2,000 people received Moderna mRNA before COVID-19 trials

“Before a single vaccine for coronavirus that we tested, we had already 2000 people Who had received mRNA from us.”

Noubar Afeyan Oct 11, 2021 ▶ 49:13 Moderna and Flagship Pioneering: Noubar Afeyan

Assertion Supported

Afeyan: Moderna designed the mRNA-1273 vaccine sequence in two days

“And to the time when we had the computer-generated sequence of the RNA, that is essentially today mRNA-twelve-seventy-three, was two days.”

Noubar Afeyan Oct 11, 2021 ▶ 53:11 Moderna and Flagship Pioneering: Noubar Afeyan

Afeyan: Celera sequenced the genome because the government project was too slow

More from Noubar Afeyan

Turn any episode into a week of clips.